Boceprevir for untreated chronic HCV genotype 1 infection

النقرات: 533
المعرّف: 117918
2011
PDF مجاني
مقاييس جودة وأداء المقال
الجودة الإجمالية
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
تقييم الجودة بالذكاء الاصطناعي
لم يتم التحليل
Readership in this journal
Steady

Ranked #23 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
الملخص
The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 we …
المفتاح المرجعي
f2011theboceprevir استخدم هذا المفتاح للاستشهاد التلقائي في المخطوطة أثناء استخدام مدير المخطوطات أو مدير الأطروحات من SciMatic
المؤلفون Poordad F;McCone J;Bacon BR;Bruno S;Manns MP;Sulkowski MS;Jacobson IM;Reddy KR;Goodman ZD;Boparai N;DiNubile MJ;Sniukiene V;Brass CA;Albrecht JK;Bronowicki JP; ;;
مجلة The New England journal of medicine
السنة 2011
DOI
DOI غير موجود
URL
http://www.ncbi.nlm.nih.gov/pubmed/21449783
الكلمات المفتاحية
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Comparative Study Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study Genotype viral / blood drug therapy combination antiviral agents / therapeutic use* recombinant proteins viral load ribavirin / therapeutic use hepacivirus / isolation & purification chronic / virology african continental ancestry group antiviral agents / adverse effects hepacivirus / genetics* chronic / drug therapy* interferon alpha-2 serine proteinase inhibitors / adverse effects serine proteinase inhibitors / therapeutic use* pmid:21449783 pmc3766849 doi:10.1056/nejmoa1010494 fred poordad jonathan mccone sprint-2 investigators anemia / chemically induced chronic / ethnology interferon-alpha / therapeutic use polyethylene glycols / therapeutic use proline / adverse effects proline / analogs & derivatives* proline / therapeutic use

الاستشهادات

لم يتم العثور على استشهادات. لإضافة استشهاد، تواصل مع المشرف على info@scimatic.org

التعليقات

لا توجد تعليقات بعد. كن أول من يعلق على هذا المقال.